Literature DB >> 6451469

Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.

S Suzuki, Y Hongu, H Fukazawa, S Ichihara, H Shimizu.   

Abstract

Distribution of 5-fluorouracil (5-FU) in various tissues including transplanted tumors was examined 1, 3 (or 4), and 24 hr after a single oral dose of 5'-deoxy-5-fluorouridine (5'-DFUR), Ftorafur (FT-207), or 5-FU itself to groups of mice bearing sarcoma-180 and of rats bearing Walker carcinoma-256. The levels of 5-FU derived from 5'-DFUR were highest in the tumors among the tissues examined 3 (or 4) and 24 hr after administration. At the 1st hr after dosing the 5-FU level in the small intestine was close to, but that in other tissues was much lower than, the 5-FU level in the tumor of both types. Such a selective distribution of 5-FU in tumor tissues was not observed after dosing of either FT-207 or 5-FU itself. Since the anticancer effect of 5'-DFUR is likely to be manifested after its conversion to 5-FU, the 5'-deoxyribose moiety of 5'-DFUR may be deemed as an efficient carrier by which the 5-FU moiety is conveyed selectively to cancer tissues.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6451469

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  8 in total

1.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Capecitabine.

Authors:  D R Budman
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA.

Authors:  Y Kato; S Matsukawa; R Muraoka; N Tanigawa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

6.  New approach to metabolism of 5'-deoxy-5-fluorouridine in humans with fluorine-19 NMR.

Authors:  M C Malet-Martino; R Martino; A Lopez; J P Béteille; M Bon; J Bernadou; J P Armand
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents.

Authors:  S Suga; K Kimura; Y Yokoyama; K Isobe; Y Yoshida; T Takada; A Sato; T Kuwabara; H Iwase
Journal:  Gastroenterol Jpn       Date:  1982

8.  Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.

Authors:  T Ishikawa; Y Tanaka; H Ishitsuka; T Ohkawa
Journal:  Jpn J Cancer Res       Date:  1989-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.